All Stories

  1. The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors

    Article • Neuroendocrinology, December 2019, Karger Publishers

    Dr Jerome Cros

  2. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

    Article • Cancers, November 2019, MDPI AG

    Dr Jerome Cros

  3. High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter

    Article • Non-Coding RNA, August 2019, MDPI AG

    Dr Jerome Cros

  4. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor

    Article • Neuroendocrinology, May 2019, Karger Publishers

    Dr Jerome Cros

  5. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses

    Article • Neuroendocrinology, February 2019, Karger Publishers

    Dr Jerome Cros

  6. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset

    Article • Cancers, January 2019, MDPI AG

    Dr Jerome Cros

  7. Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma

    Article • The Journal of Pathology, December 2018, Wiley

    Dr Marie Tosolini, Dr Jerome Cros

  8. COMPETITIVE TESTING THE WHO 2010 VS THE WHO 2017 GRADING OF PANCREAS NEUROENDOCRINE NEOPLASIA: DATA FROM A LARGE INTERNATIONAL COHORT STUDY

    Article • Neuroendocrinology, October 2018, Karger Publishers

    Dr Jerome Cros, Prof Wouter WW de Herder

  9. La caractérisation moléculaire définit plusieurs sous-types d’adénocarcinome canalaire du pancréas

    Article • Bulletin du Cancer, January 2018, Elsevier

    Dr Jerome Cros

  10. Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study

    Article • Liver International, September 2017, Wiley

    Dr Jerome Cros

  11. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation

    Article • Neuroendocrinology, August 2017, Karger Publishers

    Dr Jerome Cros

  12. Tumor Heterogeneity in Pancreatic Adenocarcinoma

    Article • Pathobiology, August 2017, Karger Publishers

    Dr Jerome Cros

  13. The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections

    Article • Journal of the American College of Surgeons, August 2017, Elsevier

    Dr Jerome Cros

  14. 5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours

    Article • Pancreatology, July 2017, Elsevier

    Dr Jerome Cros

  15. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker

    Article • Cellular and Molecular Life Sciences, June 2017, Springer Science + Business Media

    Dr Jerome Cros

  16. Surgical Ampullectomy with Complete Resection of the Common Bile Duct: a New Procedure for Radical Resection of Non-invasive Ampulloma with Biliary Extension

    Article • Journal of Gastrointestinal Surgery, May 2017, Springer Science + Business Media

    Dr Jerome Cros

  17. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

    Article • Neuroendocrinology, January 2017, Karger Publishers

    Dr Jerome Cros

  18. Investigation at the micrometer scale of pancreatic calcifications in chronic pancreatitis by μFTIR spectroscopy and field emission scanning electron microscopy

    Article • Comptes Rendus Chimie, November 2016, Elsevier

    Dr Jerome Cros

  19. Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria

    Article • Malaria Journal, September 2016, Springer Science + Business Media

    Dr Jerome Cros

  20. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging

    Article • European Radiology, August 2016, Springer Science + Business Media

    Dr Hossein Lotfalizadeh, Dr Jerome Cros

  21. Pancreatic ductal adenocarcinoma inBRCA2mutation carriers: Table 1

    Article • Endocrine Related Cancer, August 2016, Bioscientifica

    Dr Jerome Cros

  22. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

    Article • Endocrine Related Cancer, June 2016, Bioscientifica

    Dr Jerome Cros

  23. Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas

    Article • United European Gastroenterology Journal, June 2016, SAGE Publications

    Dr Enrique Perez-Cuadrado Robles, Dr Jerome Cros

  24. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma

    Article • Virchows Archiv, June 2016, Springer Science + Business Media

    Dr Jerome Cros

  25. Well differentiated pancreatic neuroendocrine tumors (WDPNET) G3: Does the Ki67 really do it all?

    Article • Pancreatology, June 2016, Elsevier

    Dr Jerome Cros

  26. Metabolic state may define and predict resistance to mTOR-targeting therapies in pancreatic neuroendocrine tumors

    Article • Pancreatology, June 2016, Elsevier

    Dr Jerome Cros

  27. Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients

    Article • Human Pathology, June 2016, Elsevier

    Dr Jerome Cros

  28. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution

    Article • Oncotarget, May 2016, Impact Journals, LLC

    Dr Jerome Cros

  29. State of the art and future directions of pancreatic ductal adenocarcinoma therapy

    Article • Pharmacology & Therapeutics, November 2015, Elsevier

    Dr Jerome Cros

  30. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma

    Article • Pancreas, October 2015, Wolters Kluwer Health

    Dr Jerome Cros

  31. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors

    Article • Neuroendocrinology, September 2015, Karger Publishers

    Dr Jerome Cros

  32. Parenchyma-sparing pancreatectomies for pancreatic neuroendocrine tumors

    Article • International Journal of Endocrine Oncology, August 2015, Future Medicine

    Dr Jerome Cros

  33. Abstract 580: hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A comparative analysis of the murine and the rabbit antibodies

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  34. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place

    Article • Annals of Surgery, August 2015, Wolters Kluwer Health

    Dr Jerome Cros

  35. Gly388Arg FGFR4 polymorphism is not predictive of everolimus efficacy in well-differentiated digestive neuroendocrine tumors

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  36. Comparative analysis between Sendai guidelines and the European experts consensus statement on BD-IPMN of the pancreas

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  37. Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  38. Neoadjuvant gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC): A promising management

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  39. Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors

    Article • Annals of Internal Medicine, May 2015, American College of Physicians

    Dr Jerome Cros

  40. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

    Article • Histopathology, May 2015, Wiley

    Dr Jerome Cros

  41. Tu1942 hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready yet? A Comparative Analysis of the Murine and the Rabbit Antibodies

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  42. Tu1918 Correlation Between the 18F-FDG Uptake Assessed by PET/CT and Pathological Data in Well-Differentiated Digestive Neuroendocrine Tumors

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  43. 665 Contrast Harmonic Endoscopic Ultrasonography Is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  44. Targeting the TGFβ pathway for cancer therapy

    Article • Pharmacology & Therapeutics, March 2015, Elsevier

    Dr Jerome Cros

  45. Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

    Article • Clinical Cancer Research, December 2014, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  46. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies

    Article • Histopathology, December 2014, Wiley

    Dr Jerome Cros

  47. Experimental evidence for IS1294b-mediated transposition of the blaCMY-2 cephalosporinase gene in Enterobacteriaceae

    Article • Journal of Antimicrobial Chemotherapy, November 2014, Oxford University Press (OUP)

    Dr Jerome Cros

  48. Lessons From McCune-Albright Syndrome–Associated Intraductal Papillary Mucinous Neoplasms

    Article • JAMA Surgery, August 2014, American Medical Association (AMA)

    Dr Jerome Cros

  49. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs)

    Article • European Radiology, June 2014, Springer Science + Business Media

    Dr Jerome Cros

  50. Long-term outcome of pancreatic neuroendocrine tumours (PNET) in von Hippel-Lindau (VHL) compared to sporadic PNET : implications for management

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  51. Evaluation of tumor response to targeted therapies in precision-cut slices of human pancreatic neuroendocrine tumors

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  52. O6-methylguanine DNA methyltransferase (MGMT) expression and Ki67 index predict response to temozolomide in patients with well differentiated pancreatic neuroendocrine tumors (WDPNET)

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  53. c-MET as a prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  54. 327 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki67 Index Predict Response to Temozolomide in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)

    Article • Gastroenterology, May 2014, Elsevier

    Dr Jerome Cros

  55. Reappraisal of Central Pancreatectomy

    Article • JAMA Surgery, April 2014, American Medical Association (AMA)

    Dr Jerome Cros

  56. MEK in cancer and cancer therapy

    Article • Pharmacology & Therapeutics, February 2014, Elsevier

    Dr Jerome Cros

  57. Hepatobiliary and Pancreatic Neoplasms in Patients With McCune-Albright Syndrome

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2014, Endocrine Society

    Dr Jerome Cros

  58. Survival time estimation using Injury Severity Score (ISS) in homicide cases

    Article • Forensic Science International, December 2013, Elsevier

    Dr Philippe Charlier, Dr Jerome Cros

  59. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors

    Article • Journal of Hepatology, December 2013, Elsevier

    Dr Jerome Cros

  60. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours

    Article • Annals of Oncology, August 2013, Oxford University Press (OUP)

    Dr Jerome Cros

  61. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma

    Article • European Journal of Cancer, August 2013, Elsevier

    Dr Jerome Cros

  62. Stromal expression of SPARC in pancreatic adenocarcinoma

    Article • Cancer and Metastasis Reviews, May 2013, Springer Science + Business Media

    Dr Jerome Cros

  63. Tu1239 Postoperative Recurrence in Patients Operated on for Benign Intraductal Papillary Mucinous Neoplasms (IPMN)

    Article • Gastroenterology, May 2013, Elsevier

    Dr Jerome Cros

  64. Mo1404 Solid Pancreatic Tumors in Young Patients (< 40 Years Old): What Is Your Diagnosis ?

    Article • Gastroenterology, May 2013, Elsevier

    Dr Jerome Cros

  65. Postoperative recurrence in patients operated on for benign intraductal papillary mucinous neoplasms (IPMN)

    Article • Pancreatology, May 2013, Elsevier

    Dr Jerome Cros

  66. Master 2 (recherche). Tout ce que vous avez toujours voulu savoir sans jamais oser le demander !

    Article • Annales de Pathologie, April 2013, Elsevier

    Dr Jerome Cros

  67. Les carcinomes des glandes salivaires : description histologique des principaux sous-types histologiques

    Article • Revue Francophone des Laboratoires, January 2013, Elsevier

    Dr Jerome Cros

  68. Homicidal Deaths in the Western Suburbs of Paris

    Article • American Journal of Forensic Medicine & Pathology, December 2012, Wolters Kluwer Health

    Dr Philippe Charlier, Dr Jerome Cros

  69. Methylguanine DNA methyl transferase (MGMT) expression predicts response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs)

    Article • Pancreatology, November 2012, Elsevier

    Dr Jerome Cros

  70. Radiographic Examination Using an X-ray Tunnel (Passagix) Before a Forensic Autopsy

    Article • American Journal of Forensic Medicine & Pathology, March 2012, Wolters Kluwer Health

    Dr Philippe Charlier, Dr Jerome Cros

  71. Rôle de l’angiogenèse et rationnel d’utilisation des thérapies ciblées dans les tumeurs endocrines digestives

    Article • Cancéro digest, January 2012, INIST-CNRS

    Dr Jerome Cros

  72. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors

    Article • Immunity, September 2010, Elsevier

    Dr Jerome Cros, Nicolas Cagnard

  73. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

    Article • Oncotarget, May 2010, Impact Journals, LLC

    Dr Jerome Cros

  74. Carcinome épidermoïde des voies aérodigestives supérieures : quoi de neuf en 2009

    Article • Annales de Pathologie, September 2009, Elsevier

    Dr Jerome Cros

  75. Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus

    Article • Cancer Research, September 2007, American Association for Cancer Research (AACR)

    Professor Luis Martinez-Sobrido, Dr Jerome Cros

  76. Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector

    Article • Journal of Virology, February 2006, ASM Journals

    Professor Luis Martinez-Sobrido, Dr Jerome Cros

  77. Inhibition of Beta Interferon Induction by Severe Acute Respiratory Syndrome Coronavirus Suggests a Two-Step Model for Activation of Interferon Regulatory Factor 3

    Article • Journal of Virology, February 2005, ASM Journals

    Professor Luis Martinez-Sobrido, Friedemann Weber, Dr Jerome Cros

  78. An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein

    Article • Traffic, January 2005, Wiley

    Dr Jerome Cros

  79. Mapping of the RNA promoter of Newcastle disease virus

    Article • Virology, January 2005, Elsevier

    Dr Jerome Cros

  80. Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors

    Article • Journal of Virology, September 2004, ASM Journals

    Dr Jerome Cros

  81. Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction

    Article • Journal of Virology, September 2003, ASM Journals

    Dr Jerome Cros

  82. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses

    Article • Virus Research, September 2003, Elsevier

    Dr Jerome Cros

  83. Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins

    Article • Journal of Virology, January 2003, ASM Journals

    Dr Jerome Cros

  84. Recombinant Newcastle Disease Virus as a Vaccine Vector

    Article • Journal of Virology, December 2001, ASM Journals

    Dr Jerome Cros